President Trump’s endorsement of an experimental Covid-19 drug from Regeneron Pharmaceuticals Inc. has raised expectations for a type of medicine that could be authorized for public use within weeks or even days. Regeneron is racing against rival Eli Lilly & Co. to bring the first monoclonal antibody drug on the market to treat Covid-19 patients who aren’t sick enough to be hospitalized. Both companies said Wednesday they had asked the U.S. Food and Drug Administration to authorize use, and they had already made tens of thousands...

Source: Wall Street Journal October 09, 2020 09:31 UTC